RU2011103741A - Композиции и способы лечения заболевания сетчатки - Google Patents

Композиции и способы лечения заболевания сетчатки Download PDF

Info

Publication number
RU2011103741A
RU2011103741A RU2011103741/04A RU2011103741A RU2011103741A RU 2011103741 A RU2011103741 A RU 2011103741A RU 2011103741/04 A RU2011103741/04 A RU 2011103741/04A RU 2011103741 A RU2011103741 A RU 2011103741A RU 2011103741 A RU2011103741 A RU 2011103741A
Authority
RU
Russia
Prior art keywords
compound according
pharmaceutically acceptable
compound
acceptable salt
aryl
Prior art date
Application number
RU2011103741/04A
Other languages
English (en)
Inventor
Томас А. ДЖОРДАН (US)
Томас А. ДЖОРДАН
Джон И. ДАУЛИНГ (US)
Джон И. ДАУЛИНГ
Джон Клиффорд ЧАБАЛА (US)
Джон Клиффорд ЧАБАЛА
Original Assignee
Ньюрон Системз Инк., (Us)
Ньюрон Системз Инк.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрон Системз Инк., (Us), Ньюрон Системз Инк., filed Critical Ньюрон Системз Инк., (Us)
Publication of RU2011103741A publication Critical patent/RU2011103741A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

1. Соединение формулы IIIa: !(IIIa) ! или фармацевтически приемлемая соль соединения IIIa, где ! L представляет собой представляет ординарную связь или CH2; ! X, Y и Z, каждый независимо представляет собой N, NH, O, S, CB, CH или отсутствует, так что один из X, Y и Z представляет собой N или NH; p равно 0, 1, 2 или 3; B представляет собой атом галогена, гидроксил, карбамоил, арил или амино; ! A представляет собой ! ; и ! D представляет собой неразветвленный низший алкил. ! 2. Соединение по п.1, где один из X или Z представляет собой N, а оставшийся X или Z представляет собой O; ! Y отсутствует; ! p равно 1; ! B представляет собой атом галогена, гидроксил, карбамоил, арил или амино; ! L представляет собой одинарную связь или CH2; ! A представляет собой ! ; и ! D представляет собой неразветвтленный низший алкил. ! 3. Соединение по п.2, где L представляет собой одинарную связь. ! 4. Соединение по п.3, где X представляет собой O, и Z представляет собой N. ! 5. Соединение по п.3, где X представляет собой N, и Z представляет собой O. ! 6. Соединение по п.4 или 5, где B представляет собой арил. ! 7. Соединение по п.6, где B представляет собой фенил. ! 8. Соединение по п.3, где D представляет собой CH3. ! 9. Соединение по п.8, выбранное из ! , , ! или его фармацевтически приемлемая соль. ! 10. Соединение по п.9, которое представляет собой ! ! или его фармацевтически приемлемая соль. ! 11. Соединение по п.9, которое представляет собой ! ! или его фармацевтически приемлемая соль. ! 12. Фармацевтическая композиция, содержащая соединение по п.1 и фармацевтически приемлемый носитель. ! 13. Фармацевтическая композиция по п. 12, содержащая соединение, выбранное из !, ! или его фармацевтически приемлемую соль и фармацевти

Claims (16)

1. Соединение формулы IIIa:
Figure 00000001
(IIIa)
или фармацевтически приемлемая соль соединения IIIa, где
L представляет собой представляет ординарную связь или CH2;
X, Y и Z, каждый независимо представляет собой N, NH, O, S, CB, CH или отсутствует, так что один из X, Y и Z представляет собой N или NH; p равно 0, 1, 2 или 3; B представляет собой атом галогена, гидроксил, карбамоил, арил или амино;
A представляет собой
Figure 00000002
; и
D представляет собой неразветвленный низший алкил.
2. Соединение по п.1, где один из X или Z представляет собой N, а оставшийся X или Z представляет собой O;
Y отсутствует;
p равно 1;
B представляет собой атом галогена, гидроксил, карбамоил, арил или амино;
L представляет собой одинарную связь или CH2;
A представляет собой
Figure 00000002
; и
D представляет собой неразветвтленный низший алкил.
3. Соединение по п.2, где L представляет собой одинарную связь.
4. Соединение по п.3, где X представляет собой O, и Z представляет собой N.
5. Соединение по п.3, где X представляет собой N, и Z представляет собой O.
6. Соединение по п.4 или 5, где B представляет собой арил.
7. Соединение по п.6, где B представляет собой фенил.
8. Соединение по п.3, где D представляет собой CH3.
9. Соединение по п.8, выбранное из
Figure 00000003
,
Figure 00000004
,
или его фармацевтически приемлемая соль.
10. Соединение по п.9, которое представляет собой
Figure 00000003
или его фармацевтически приемлемая соль.
11. Соединение по п.9, которое представляет собой
Figure 00000004
или его фармацевтически приемлемая соль.
12. Фармацевтическая композиция, содержащая соединение по п.1 и фармацевтически приемлемый носитель.
13. Фармацевтическая композиция по п. 12, содержащая соединение, выбранное из
Figure 00000003
,
Figure 00000004
или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
14. Соединение, которое представляет собой
Figure 00000003
или его фармацевтически приемлемая соль.
15. Соединение, которое представляет собой
Figure 00000004
или его фармацевтически приемлемая соль.
16. Применение соединения по п.9 в производстве лекарственного средства для лечения дегенерации желтого пятна и других форм заболевания сетчатки, этиология которых включает накопление А2Е и/или липофусцина в ткани сетчатки у субъекта, причем указанное лекарственное средство снижает уровень накопления А2Е по отношению к уровню накопления А2Е у субъекта в отсутствии лекарственного средства.
RU2011103741/04A 2005-05-26 2011-02-02 Композиции и способы лечения заболевания сетчатки RU2011103741A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68546005P 2005-05-26 2005-05-26
US60/685,460 2005-05-26
US72357705P 2005-10-04 2005-10-04
US60/723,577 2005-10-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2007148994/04A Division RU2419610C2 (ru) 2005-05-26 2006-05-26 Композиции и способы лечения заболевания сетчатки

Publications (1)

Publication Number Publication Date
RU2011103741A true RU2011103741A (ru) 2012-08-10

Family

ID=36928994

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2007148994/04A RU2419610C2 (ru) 2005-05-26 2006-05-26 Композиции и способы лечения заболевания сетчатки
RU2011103741/04A RU2011103741A (ru) 2005-05-26 2011-02-02 Композиции и способы лечения заболевания сетчатки

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2007148994/04A RU2419610C2 (ru) 2005-05-26 2006-05-26 Композиции и способы лечения заболевания сетчатки

Country Status (14)

Country Link
US (12) US8940764B2 (ru)
EP (3) EP2325171B1 (ru)
JP (1) JP5042215B2 (ru)
KR (1) KR101342547B1 (ru)
CN (1) CN101321742B (ru)
AU (1) AU2006249866B2 (ru)
BR (1) BRPI0610308A8 (ru)
CA (1) CA2609659C (ru)
ES (2) ES2393768T3 (ru)
HK (1) HK1113797A1 (ru)
PL (1) PL1888548T3 (ru)
PT (1) PT1888548E (ru)
RU (2) RU2419610C2 (ru)
WO (1) WO2006127945A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707071B2 (en) 2004-11-24 2017-07-18 Contego Medical Llc Percutaneous transluminal angioplasty device with integral embolic filter
US9510930B2 (en) 2008-10-22 2016-12-06 Contego Medical, Llc Angioplasty device with embolic filter
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
DK2187880T3 (da) 2007-09-12 2014-03-10 Univ Columbia Sammensætninger og fremgangsmåder til behandling af makuladegeneration
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CA2782015C (en) * 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
KR101016018B1 (ko) 2010-02-18 2011-02-23 주식회사 세코닉스 피코 프로젝터용 투사 렌즈 유닛
RU2015120478A (ru) 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
KR102435676B1 (ko) * 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
JP6266023B2 (ja) * 2013-01-25 2018-01-24 アルデイラ セラピューティクス， インコーポレイテッド 黄斑変性症の処置における新規トラップ
CA2913582A1 (en) 2013-05-30 2014-12-04 Mor Research Applications Ltd. Compositions and methods for treatment of retinal degenerative diseases
US10682328B2 (en) 2014-12-03 2020-06-16 Mor Research Applications Ltd. Compositions and methods for treatment of retinal degenerative diseases
KR20180073553A (ko) * 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 알데히드 접합체 및 이의 용도
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CN109069530A (zh) 2016-02-28 2018-12-21 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2018039197A1 (en) * 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
EP3500256A4 (en) * 2016-08-22 2020-01-08 Aldeyra Therapeutics, Inc. ALDEHYDE CAPTURE CONNECTIONS AND USES THEREOF
KR101846730B1 (ko) 2016-11-01 2018-04-06 현대자동차주식회사 영상표시장치 마운팅 구조
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US20220133697A1 (en) * 2018-12-05 2022-05-05 Aldeyra Therapeutics, Inc. Injectable formulations
US20220009893A1 (en) 2018-12-12 2022-01-13 Teva Pharmaceuticals International Gmbh Solid state forms of reproxalap
EP3901138A4 (en) * 2018-12-18 2022-10-05 Medshine Discovery Inc. COMPOUND FOR USE IN RETINAR DISEASES
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US20220089542A1 (en) * 2019-05-02 2022-03-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US20230021669A1 (en) * 2019-12-30 2023-01-26 The National Institutes of Pharmaceutical R&D Co., Ltd. Tricyclic compound, and preparation method therefor and medical use thereof
US20230131929A1 (en) * 2020-03-24 2023-04-27 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
WO2021211625A1 (en) * 2020-04-13 2021-10-21 Aldeyra Therapeutics, Inc. Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
CN115702144A (zh) * 2020-06-17 2023-02-14 南京明德新药研发有限公司 氨基吡啶类化合物
KR20230128056A (ko) * 2020-12-29 2023-09-01 더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드 삼환식 화합물, 및 그의 제조 방법 및 그의 의학적용도

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) * 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
JPS6192592A (ja) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) * 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2072001C (en) 1990-10-22 1998-11-03 Nimai C. De Method and composition for cleaning contact lenses
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
JP2746832B2 (ja) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 眼局所抗アレルギー剤
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
CN1228084A (zh) 1996-08-01 1999-09-08 道农业科学公司 具有杀菌活性的4－取代的喹啉衍生物
PL331602A1 (en) 1996-08-06 1999-08-02 Pfizer Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
EP0980362B1 (de) * 1997-05-02 2006-08-16 Schering Aktiengesellschaft Substituierte heterocyclen und deren verwendung in arzneimitteln
GB2327672A (en) * 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
EP1012151B1 (en) 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP3568108B2 (ja) 1999-07-28 2004-09-22 松下電器産業株式会社 デジタル地図の位置情報伝達方法とそれを実施する装置
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
WO2001041757A1 (fr) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Composition pharmaceutique contenant de la cyclodextrine
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP4748289B2 (ja) 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
EP1610772A4 (en) 2003-03-14 2008-06-18 Univ Washington RETINOID REPLACEMENT AND OPSIN AGONISTS AND METHOD OF USE THEREOF
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
EP2305308A1 (en) 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
EP1678160A1 (en) 2003-10-27 2006-07-12 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
WO2005051328A2 (en) 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration of macular degeneration and other ophthalmic diseases
JP2005187407A (ja) 2003-12-25 2005-07-14 Lion Corp アレルギー眼疾患用眼科組成物
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
BRPI0507807A (pt) 2004-02-17 2007-07-31 Harvard College gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
JP2008518913A (ja) 2004-10-28 2008-06-05 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子
WO2006077821A1 (ja) * 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. アルドステロン受容体調節剤としての芳香族スルホン化合物
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
JP5196130B2 (ja) 2005-12-27 2013-05-15 ライオン株式会社 ソフトコンタクトレンズ用組成物及び吸着抑制方法
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
CA2683756A1 (en) 2006-04-14 2007-10-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration(amd)
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
WO2008014602A1 (en) 2006-07-25 2008-02-07 Envivo Pharmaceuticals, Inc. Quinoline derivatives
US7956189B2 (en) 2006-08-14 2011-06-07 Schering Corporation Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore
CA2661683C (en) 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
TW200914437A (en) 2007-06-20 2009-04-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
CA2701116C (en) 2007-10-05 2013-02-05 Acucela Inc. Alkoxy compounds for disease treatment
KR101810381B1 (ko) 2008-02-11 2017-12-19 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 연령-관련 망막 기능장애의 치료 및 예방 방법
AU2009282076A1 (en) 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
NZ592993A (en) 2008-10-22 2013-02-22 Acucela Inc Compounds for treating ophthalmic diseases and disorders
NZ591999A (en) 2008-11-11 2013-06-28 Novartis Ag Salts of fingolimod fty720
JP2012520880A (ja) 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2010148351A1 (en) 2009-06-18 2010-12-23 Cylene Pharmaceuticals, Inc. Rhodanines and related heterocycles as kinase inhibitors
WO2011008202A1 (en) 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
JPWO2011078204A1 (ja) 2009-12-24 2013-05-09 浜理薬品工業株式会社 高脂血症の予防または治療剤、および抗疲労剤
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
EP2611782A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
CN106749023A (zh) 2011-01-12 2017-05-31 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
US10463687B2 (en) 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
US9302013B2 (en) 2011-01-31 2016-04-05 Termira Ab Active principle for mitigating undesired medical conditions
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
WO2015187942A1 (en) 2014-06-04 2015-12-10 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
AU2013296420B2 (en) 2012-08-01 2017-12-07 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
CN104884049A (zh) 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
RU2015120478A (ru) 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
CA2897467C (en) 2013-01-23 2020-09-22 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
JP6266023B2 (ja) 2013-01-25 2018-01-24 アルデイラ セラピューティクス， インコーポレイテッド 黄斑変性症の処置における新規トラップ
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9713330B1 (en) 2013-03-15 2017-07-25 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
JP6634034B2 (ja) 2014-06-25 2020-01-22 シネルジア・バイオ・サイエンシーズ・プライベイト・リミテッドＳｙｎｅｒｇｉａ Ｂｉｏ Ｓｃｉｅｎｃｅｓ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 医薬水中油型ナノエマルジョン
NO2721710T3 (ru) 2014-08-21 2018-03-31
JP2017527614A (ja) 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders
US10351559B2 (en) 2015-04-15 2019-07-16 Beigene, Ltd. Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
KR20180073553A (ko) 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 알데히드 접합체 및 이의 용도
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CN109069530A (zh) 2016-02-28 2018-12-21 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2017214201A1 (en) 2016-06-06 2017-12-14 Thesan Pharmaceuticals, Inc. Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same
EP3500256A4 (en) 2016-08-22 2020-01-08 Aldeyra Therapeutics, Inc. ALDEHYDE CAPTURE CONNECTIONS AND USES THEREOF
WO2018039197A1 (en) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
JP7030345B2 (ja) 2016-09-28 2022-03-07 メディコン ファーマシューティカルズ，インコーポレイテッド 眼の状態を処置する組成物および方法
CA3036587A1 (en) 2016-10-05 2018-04-12 Mitobridge, Inc. Crystalline and salt forms of ppar agonist compounds
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
WO2020018498A1 (en) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020072621A1 (en) 2018-10-02 2020-04-09 Aldeyra Therapeutics, Inc. Contact lens solutions and kits
US20220133697A1 (en) 2018-12-05 2022-05-05 Aldeyra Therapeutics, Inc. Injectable formulations
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US20220089542A1 (en) 2019-05-02 2022-03-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US20230131929A1 (en) 2020-03-24 2023-04-27 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
CN115943314A (zh) 2020-06-04 2023-04-07 奥尔德拉医疗公司 干眼病生物标志物及其治疗用途

Also Published As

Publication number Publication date
JP2008542291A (ja) 2008-11-27
EP2325171B1 (en) 2013-10-09
US11724987B2 (en) 2023-08-15
US20150209345A1 (en) 2015-07-30
CA2609659A1 (en) 2006-11-30
RU2419610C2 (ru) 2011-05-27
US7973025B2 (en) 2011-07-05
AU2006249866A1 (en) 2006-11-30
EP2325171A1 (en) 2011-05-25
US20180194733A1 (en) 2018-07-12
US9364471B2 (en) 2016-06-14
US10202348B2 (en) 2019-02-12
US20150209333A1 (en) 2015-07-30
US20110263645A1 (en) 2011-10-27
US20240174614A1 (en) 2024-05-30
CN101321742B (zh) 2012-08-29
US20160168098A1 (en) 2016-06-16
US10913722B2 (en) 2021-02-09
EP1888548B1 (en) 2012-08-22
KR101342547B1 (ko) 2013-12-17
US20070135481A1 (en) 2007-06-14
ES2441873T3 (es) 2014-02-06
BRPI0610308A2 (pt) 2010-11-09
US20090182009A1 (en) 2009-07-16
CN101321742A (zh) 2008-12-10
ES2393768T3 (es) 2012-12-27
US9650342B2 (en) 2017-05-16
AU2006249866B2 (en) 2011-10-13
PT1888548E (pt) 2012-10-30
KR20080081806A (ko) 2008-09-10
HK1113797A1 (en) 2008-10-17
EP2336117A1 (en) 2011-06-22
US8940764B2 (en) 2015-01-27
US9896419B2 (en) 2018-02-20
US9265759B2 (en) 2016-02-23
WO2006127945A1 (en) 2006-11-30
US20170320829A1 (en) 2017-11-09
US20210269402A1 (en) 2021-09-02
US8940721B2 (en) 2015-01-27
US20190210971A1 (en) 2019-07-11
EP1888548A1 (en) 2008-02-20
PL1888548T3 (pl) 2013-01-31
JP5042215B2 (ja) 2012-10-03
US20230041335A1 (en) 2023-02-09
BRPI0610308A8 (pt) 2017-04-25
CA2609659C (en) 2014-01-28
RU2007148994A (ru) 2009-07-10

Similar Documents

Publication Publication Date Title
RU2011103741A (ru) Композиции и способы лечения заболевания сетчатки
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
US7105567B2 (en) 3-substituted urea derivatives and medicinal use thereof
JP2009504763A5 (ru)
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
RU2018106914A (ru) 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
JP2005506352A5 (ru)
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
RU2004110055A (ru) Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов
RU2008105481A (ru) Новое применение активаторов и стимуляторов растворимой гуанилатциклазыдля профилактики или лечения почечных расстройств
JP2008521827A5 (ru)
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2004516314A5 (ru)
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
CY1113890T1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
RU2008126245A (ru) Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции
RU2007125659A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
JP2019535723A5 (ru)
RU2008129641A (ru) Ингибиторы ccr9 активности
JP2005527605A5 (ru)
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
RU2008113187A (ru) Лечение аутоиммунных заболеваний

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20140203